Show simple item record

dc.contributor.authorDoshi, Peter
dc.date.accessioned2017-05-25T01:18:37Z
dc.date.available2017-05-25T01:18:37Z
dc.date.issued2009-12-08
dc.identifier.citationDoshi P. (2009). Neuraminidase inhibitors--the story behind the Cochrane review. BMJ 2009;339:b5164. DOI: https://doi.org/10.1136/bmj.b5164en_US
dc.identifier.urihttp://hdl.handle.net/10713/6612en_US
dc.descriptionAlthough billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the storyen_US
dc.description.urihttp://bmj.com/cgi/content/full/bmj.b5164?ijkey=IJj0Y9z5v4LN0Ts&keytype=refen_US
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.subjectneuraminidase inhibitorsen_US
dc.subjectTamifluen_US
dc.subjectpublic health policyen_US
dc.subjectdrug efficacyen_US
dc.subject.lcshSystematic reviews (Medical research)en_US
dc.subject.meshInfluenza, Human--drug therapyen_US
dc.subject.meshOseltamiviren_US
dc.titleNeuraminidase inhibitors--the story behind the Cochrane reviewen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmj.b5164
dc.identifier.pmid19995813
dc.identifier.ispublishedNoen_US
dc.description.urinameClick here for the free full-text article on publisher’s websiteen_US
refterms.dateFOA2019-02-19T18:16:27Z


Files in this item

Thumbnail
Name:
Doshi_BMJ_Neuraminidase_Inhibi ...
Size:
503.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record